Search Results
Jul 27, 2026, 22:35 ET Akeso IO2.0 + ADC2.0 Strategy Makes Another Advancement: First Patient Dosed in Phase Ib/II Study of HER3 ADC (AK138D1) Combined with Ivonescimab in Lung Cancer
hematologic toxicity and no reported cases of interstitial lung disease (ILD).Ivonescimab, a first-in-class PD-1/VEGF bispecific antibody, has shown strong clinical results compared to PD-1 inhibitor-based therapies across multiple Phase III studies. The combination of AK138D1 with ivonescimab is expected
More news about: Akeso, Inc.
Jul 27, 2026, 07:30 ET Kelun-Biotech Receives a Clinical Trial Notice for Its First Dual-payload ADC SKB565
actively exploring high-quality combination regimens, including multiple ongoing clinical studies evaluating ADCs in combination with PD-(L)1 monoclonal antibodies, as well as the PD-1/VEGF bispecific antibody SKB118 in combination with its proprietary ADC portfolio; on the other hand, the Company is advancing
More news about: Kelun-Biotech
Jul 23, 2026, 12:45 ET aiEDU Announces 2026 Community Catalyst Grantees, Backing Educator Capacity Building Across Rural and Indigenous Communities
(Illinois) — The Rural AI Leadership Cohort, guiding 8–10 districts through a strategic planning process to adopt local AI guidance and build actionable PD rollout plans.Montana Digital Academy / Frontier Learning Lab (Montana) — Training 23 teacher leaders at one-room schoolhouses
More news about: aiEDU
Jul 23, 2026, 10:54 ET Toyota actualiza la Sequoia 2027 con un diseño más sofisticado, tecnología avanzada y el nuevo paquete Trailhunter, ahora disponible
capacidades de detección, y cuenta con las siguientes funciones:Sistema de prevención de colisiones con detección de peatones (PCS con PD)Control de crucero dinámico por radar (DRCC) para todo el rango de velocidadesAlerta de salida de carril con asistencia a la dirección
More news about: Toyota Motor North America
Jul 23, 2026, 08:56 ET Canada Nickel Announces Initial Mineral Resource at Nesbitt and Delivers 46% Increase in Indicated Resource at Deloro
S (%)Pd (g/t)Pt (g/t)
More news about: Canada Nickel Company Inc.
Jul 23, 2026, 08:47 ET Bio-Thera Solutions Announces First Patient Dosed in Phase 1 Study for BAT8013, an Antibody Drug Conjugate Targeting CD25 for the Treatment of Advanced Solid Tumors
potentiate the efficacy of other immune-oncology agents like PD-1 and PD-L1 mAbs.A series of preclinical studies have shown that BAT8013 has good stability and safety and has high anti-tumor activity in combination with Bio-Thera's PD-1 inhibitor, BAT1308. The small molecule topoisomerase I inhibitor
More news about: Bio-Thera Solutions, Ltd
Jul 23, 2026, 08:00 ET Toyota Updates 2027 Sequoia with Elevated Style, Advanced Technology and Newly Available Trailhunter Package
its hardware and detection capabilities and has the following features:Pre-Collision System with Pedestrian Detection (PCS w/PD) Full-Speed Range Dynamic Radar Cruise Control (DRCC) Lane Departure Alert with Steering Assist (LDA w/SA) Automatic High
More news about: Toyota Motor North America
Jul 22, 2026, 19:05 ET El nuevo modelo Tundra 2027 de Toyota se estrena con un diseño robusto y renovado, tecnología innovadora y el nuevo paquete Trailhunter
capacidades de detección y cuenta con las siguientes características:Sistema de Pre-Colisión con Detección de Peatones (PCS w/PD) Control Automático de Velocidad con Radar Dinámico (DRCC) Alerta de Cambio Involuntario de Carril con Asistencia de Dirección (LDA
More news about: Toyota Motor North America
Jul 22, 2026, 10:31 ET CAR T-Cell Therapy for Non-Hodgkin Lymphoma Market Set for Robust Growth at a CAGR of ~7% Through 2036, Driven by Expanding Indications and Clinical Adoption | DelveInsight
non-Hodgkin lymphoma (R/R B-NHL). The therapy is distinguished by its PD-1 gene knockout, making it, to current knowledge, the first allogeneic CAR-T therapy in clinical development to incorporate this genome-editing approach. By eliminating PD-1 expression, the strategy is intended to reduce premature CAR-T
More news about: DelveInsight Business Research, LLP
Jul 22, 2026, 10:04 ET Sony Electronics Launches the FX5, a Cinema Line Camera with a Newly Developed Image Sensor, Open Gate Recording, Internal RAW Recording, and Enhanced Operability
shooting.Two USB Type-C™ ports accept timecode input through an optional timecode adapter cable and external power through USB Power Delivery (PD),[9] for stable long-duration shooting.A wired LAN terminal enables remote operation and a stable network connection, with the expandability
More news about: Sony Electronics, Inc.
Jul 22, 2026, 10:00 ET SITC Announces EU Immuno-oncology Drug Development Summit - Bringing the European IO Community Together to Foster the Next Wave of IO Therapeutics
audience and audience generationLearn about key informational resources and best practices for advancing immuno-oncology therapeutics beyond PD-1/PD-L1 pathwaysNetwork with attendees from Europe, the US and around the worldAbout SITCEstablished in 1984, the
More news about: Society for Immunotherapy of Cancer (SITC)
Jul 22, 2026, 09:16 ET HKEY-AI4AI-Atlas™ 1.0: HKeyBio Uses AI to Curate Autoimmune Model Datasets
retrieval to organize HKeyBio's accumulated experience in autoimmune and allergic disease models, in vivo pharmacodynamics, pathology, immune endpoints, PK/PD, NHP responses and translational endpoints. HKEY-AI4AI-Atlas™ 1.0 at a GlanceWhat it is: HKEY-AI4AI-Atlas™ 1.0 is HKeyBio's
More news about: HKeyBio
Jul 22, 2026, 08:55 ET NYSE Content Update: CNBC + NYSE Celebrate Extension of 30-Year Partnership
BellCNBC and the NYSE celebrate 30 years of bringing audiences closer to the marketsClosing BellPagerDuty (NYSE: PD) celebrates a new chapter as John DiLullo becomes CEOFor market insights, IPO activity, and today's opening bell, download the NYSE TV App:
More news about: New York Stock Exchange
Jul 21, 2026, 08:00 ET New 2027 Toyota Tundra Brings Rugged Updated Styling, Advanced Technology and New Trailhunter Package
its hardware and detection capabilities and has the following features:Pre-Collision System with Pedestrian Detection (PCS w/PD) Full-Speed Dynamic Radar Cruise Control (DRCC) Lane Departure Alert with Steering Assist (LDA w/SA) Automatic High Beams
More news about: Toyota Motor North America
Jul 21, 2026, 07:00 ET Compugen to Participate in BTIG Biotechnology Conference 2026
adaptive platform trial as a single agent in maintenance therapy in relapsed platinum sensitive ovarian cancer (named MAIA-ovarian trial). Rilvegostomig, a PD-1/TIGIT bispecific antibody with a TIGIT component that is derived from COM902, Compugen's anti-TIGIT antibody, is being developed by AstraZeneca pursuant
More news about: Compugen Ltd.
Jul 21, 2026, 06:00 ET Phanes Therapeutics Announces Expansion of Clinical Trial Collaboration and Supply Agreement with Merck to Evaluate Spevatamig in Combination with KEYTRUDA® (Pembrolizumab) and Chemotherapy for Treatment of Biliary Tract Cancer
expanded their clinical trial collaboration with Merck (known as MSD outside of the US and Canada) to study spevatamig in combination with Merck's anti-PD-1 therapy, KEYTRUDA® (pembrolizumab), and chemotherapy in 1L BTC.
More news about: Phanes Therapeutics, Inc.
Jul 20, 2026, 09:00 ET Argo Biopharma Doses First Participant in Phase I Clinical Trial of Factor XI Targeting siRNA Therapy BW-41012
double-blind, placebo-controlled, single ascending dose (SAD) study designed to evaluate the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of subcutaneous administration of BW-41012 in healthy volunteers in Australia. The study will assess safety and biomarkers of biological activity, including
More news about: Argo Biopharmaceutical Co., Ltd
Jul 20, 2026, 07:30 ET Biohaven to Present New Clinical Data at ESMO Congress on BHV-1530, a Novel FGFR3-Directed ADC With a Proprietary Topoisomerase I (TopoIx) Payload
overexpression seen in approximately 50% of metastatic urothelial cancer cases as well as other tumor types that overexpress FGFR3. Anti-PD-1 combination cohorts planned: Biohaven has entered into a clinical supply agreement with Regeneron Pharmaceuticals, Inc. to evaluate BHV-1530
More news about: Biohaven Ltd.
Jul 20, 2026, 07:00 ET Marengo Secures ESMO 2026 Oral Presentation for Key Phase 2 Invikafusp Alfa Data in PD-1-Resistant Solid Tumors and Appoints Pembrolizumab Development Leader Eric Rubin, M.D., to Scientific Advisory Board
are refractory or resistant to PD-1–directed therapy. Building on data reported at SITC 2025, the results will further assess whether selective activation of Vβ6/Vβ10 T-cell subsets in vivo can generate single-agent activity across biomarker-enriched tumor types after PD-1 resistance."Selection
More news about: Marengo Therapeutics
Jul 20, 2026, 07:00 ET Compugen to Release Second Quarter 2026 Results on Monday, August 3, 2026
adaptive platform trial as a single agent in maintenance therapy in relapsed platinum sensitive ovarian cancer (named MAIA-ovarian trial). Rilvegostomig, a PD-1/TIGIT bispecific antibody with a TIGIT component that is derived from COM902, Compugen's anti-TIGIT antibody, is being developed by AstraZeneca pursuant
More news about: Compugen Ltd.
Jul 20, 2026, 03:00 ET Antengene Announces Poster Presentation of ATG-022 and ATG-037 at ESMO 2026
commercial stages, with key investigational candidates including ATG-022 (CLDN18.2 ADC), ATG-037 (oral CD73 inhibitor), ATG-101 (PD-L1 x 4-1BB bispecific antibody), ATG-125 (B7-H3 × PD-L1 bispecific ADC), ATG-207 (αCD3-TGF-β bifunctional fusion protein), as well as T cell engager (TCE) programs developed using
More news about: Antengene Corporation Limited
Jul 20, 2026, 01:32 ET Akeso Doses First Patient in Phase II Study of Novel TROP2/Nectin-4 Bispecific ADC (AK146D1) in Combination with Ivonescimab for Advanced NSCLC
conventional ADCs, effectively ushering ADC therapy into a new 2.0 era.Ivonescimab, a first-in-class PD-1/VEGF bispecific antibody, has demonstrated clinically transformative benefits compared to PD-1 inhibitor-based therapies across multiple Phase III studies, supported by a robust body of clinical
More news about: Akeso, Inc.
Jul 17, 2026, 08:00 ET SystImmune Announces Second Approval of Iza-bren in China for the Treatment of Recurrent or Metastatic Esophageal Squamous Cell Carcinoma
with recurrent or metastatic esophageal squamous cell carcinoma (ESCC) whose disease has progressed following prior platinum-based chemotherapy and PD-1/PD-L1 inhibitor therapy.
More news about: SystImmune, Inc.
Jul 15, 2026, 09:00 ET Cellular Intelligence Expands Leadership Team with Seasoned AI and Biotech Industry Executives
company acquired STEM-PD, an investigational Phase 2-ready Parkinson's disease cell therapy program, from Novo Nordisk. STEM-PD gives Cellular Intelligence its own path to patients and works as a proving ground for the company's technology platform. The platform, combined with the STEM-PD program, is designed
More news about: Cellular Intelligence
Jul 15, 2026, 09:00 ET Solution Tree Books Earn Bronze in Both Foreword INDIES and IPPY Awards
Global PD Teams and
More news about: Solution Tree